Identification of enzyme resistance mechanisms in pathogens from an outpatient clinic in a public hospital in San Lorenzo, Paraguay; 2015-2019
DOI:
https://doi.org/10.18004/anales/2020.053.02.25Keywords:
antimicrobial resistance, ESBL, carbapenemases, MBL, urinary tract infection (UTI), KPC, ParaguayAbstract
Introduction: The objective of this study was to assess frequency of enzymatic resistance mechanisms isolated from community urinary tract infections (UTI) determined in vitro in urine cultures. Objectives: This is a retrospective study, a total of 1031 urine samples were included from patients with urinary tract infection who had consulted at the Outpatient Clinic and Emergencies Services. The following information was recorded, age, sex, urine sample. All urine cultures in which pathogens with a count of ≥ 105 CFU / mL were included. Were excluded polymicrobial urine cultures, those without an antibiogram or those with incomplete clinical data. Results: A total of 1031 urine samples met inclusion criteria, 56% of patients were female and 43% male. The mean age of the women was 52 ± 20 years and in men was 62 ± 16 years. 553 (52%) E. coli and 148 (14%) Klebsiella strains were isolated from community samples. Male urine cultures: The main resistance mechanism of Escherichia coli was ESBLs, 55 isolates (91%); followed by MBL, 3 isolates (5%) and KPC, 2 isolates (3%). In Klebsiella pneumoniae (53 isolates); ESBL, 31 isolates (58%); followed by KPC 13 isolates (25%) and MBL, 9 isolates in (16%). Female urine culture: Escherichia coli enzymes 81 isolates, of which ESBLs were 79 isolates (97%); followed by KPC, 1 isolate (1%) and MBL, 1 isolate (1%). In Klebsiella pneumoniae the following enzymatic mechanisms could be observed based on 35 isolates; ESBL, 19 isolates (54%), followed by KPCs, 12 isolates (34%) and finally, MBL, 4 isolates (13%). Conclusion: The result of our study showed high prevalence of Escherichia coli and Klebsiella pneumoniae causing resistance to antibiotics in culture bacteria from urine samples of patients with UTI, and ESBL was the main β-lactamase resistance mechanism in Klebsiella and E. coli isolates in both male and female.
References
1. Hooper DC. Resistencia bacteriana a fármacos antimicrobianos. En: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, editores. Harrison principios de medicina interna. Vol 1. 20a ed. México: McGraw‐Hill; 2018. p. 1057‐1062.
2. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362(19):1804-1813.
3. Melgarejo LE, Valinotti VA, Lird MG, Velá zquez GR, Chírico CE, Santa Cruz FV. Estudio preliminar de Infecciones Urinarias Intrahospitalarias en Salas de Clínica Médica de un hospital público de San Lorenzo. An. Fac. Cienc. Méd. (Asunció n) 2018;51(2):17-26
4. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin;. Nature .1940;146:837
5. Fleming A. On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to their Use in the Isolation of B. influenzæ. Br J Exp Pathol. 1929;10(3):226-36.
6. Dreger NM, Degener S, Ahmad-Nejad P, Wöbker G, Roth S. Urosepsis--Etiology, Diagnosis, and Treatment. Dtsch Arztebl Int. 2015 Dec;112(49):837-47; quiz 848.
7. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162.
8. Jiang Y, Li J, Zhang Y, Hu X, Zhang X, Shang X, Gong S, Yu R. Clinical Situations of Bacteriology and Prognosis in Patients with Urosepsis. Biomed Res Int. 2019 Feb 6:3080827.
9. Ocampos Ugarte JG, Takahasi Alvarez VE. Enterobacterias productoras de carbapenemasas en pacientes del Servicio de Clínica Médica del Hospital Nacional de Itauguá. Rev. Virtual Soc. Parag. Med. Int. 2015;2(2):33-42
10. Pereira A, Fariña N, de Vega M, Gonzá lez P, Rodríguez F, de Figueredo L. Enterobacterias productoras de Betalactamasas de espectro extendido aisladas de pacientes ambulatorios y hospitalizados en un laboratorio privado de Asunción, Paraguay. Mem. Inst. Investig. Cienc. Salud. 2016;14(1):17-24
11. Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: Toward the globalization of CTX-M. Clin Microbiol Rev. 2013;26:744-58.
12. Alós JI. Resistencia bacteriana a los antibióticos: una crisis global. Enferm Infecc Microbiol Clin. 2015;33(10):692-699
13. Gumbo T. Principios generales del tratamiento antimicrobiano. En: Brunton LL, Hilal-Dandan R, Knollmann BC, editores. Goodman & Gilman, Bases farmacológicas de la terapéutica. 13a edición. McGraw-Hill; 2019. p. 957-968
14. Navarro F, Calvo J, Cantón R, Fernández-Cuenca F, Mirelisa B. Detección fenotípica de mecanismos de resistencia en microorganismos gramnegativos. Enferm Infecc Microbiol Clin . 2011;29(7):524-534
15. McDanel J, Schweizer M, Crabb V, Nelson R, Samore M, Khader K, Blevins AE, Diekema D, Chiang HY, Nair R, Perencevich E. Incidence of Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella Infections in the United States: A Systematic Literature Review. Infect Control Hosp Epidemiol. 2017;38(10):1209-1215.
16. Dahms C, Hübner NO, Kossow A, Mellmann A, Dittmann K, Kramer A. Occurrence of ESBL-Producing Escherichia coli in Livestock and Farm Workers in Mecklenburg-Western Pomerania, Germany. PLoS One. 2015;10(11):e0143326.
17. Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 2006;9(5):466-75.
18. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev . 2005 Oct;18(4):657-86.
19. Picazo JJ, Prieto J. Compendio de Microbiología. Barcelona, Elsevier, 2.a edición, 2016.
20. Jacoby GA, Munoz-Price LS. The New Lactamases. N Engl J Med 2005;352:380-91.
21. Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289(1036):321‐331
22. Bush K, Jacoby GA, Medeiros AA. A functional correlation with molecular structure. Antimicrob Agents Chemother. 1995;39(6):1211‐1233.
23. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother . 2010;54(3):969‐976.
24. Turner PJ. Extended-spectrum beta-lactamases. Clin Infect Dis . 2005;41 Suppl 4:S273‐S275.
25. Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother . 1991;35(9):1697-704.
26. Khan AU, Maryam L, Zarrilli R. Structure, Genetics and Worldwide Spread of New Delhi Metallo-beta-lactamase (NDM). BMC Microbiol. 2017; 17:101.
27. Nordmann P, Poirel L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clin Infect Dis . 2019;69(Suppl 7):S521-S528.
28. Vera-Leiva A, Barría-Loaiza C, Carrasco-Anabalón S, Lima C, Aguayo-Reyes A, Domínguez M, et al. KPC: Klebsiella pneumoniae carbapenemasa, principal carbapenemasa en enterobacterias. Rev Chilena Infectol 2017;34(5): 476-484
29. Ocampos-Ugarte JB, Takahasi-Alvarez VE. Enterobacterias productoras de carbapenemasas en pacientes del Servicio de Clínica Médica del Hospital Nacional de Itauguá. Rev. Virtual Soc. Parag. Med. Int, 2015;2(2):33-42.
30. Mano Y, Saga T, Ishii Y, Yoshizumi A, Bonomo RA, Yamaguchi K, Tateda K. Molecular analysis of the integrons of metallo-β-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan. BMC Microbiol 2015;15:41. https://doi.org/10.1186/s12866-015-0378-8
31. Bush K. Past and Present Perspectives on β-Lactamases. Antimicrob Agents Chemother . 2018;62(10):e01076-18.
32. Kass EH. Bacteriuria and the diagnosis of infections of the urinary tract; with observations on the use of methionine as a urinary antiseptic. AMA Arch Intern Med. 1957;100:709-14.
33. Picazo JJ (Editor). La infección urinaria, En: Procedimientos en Microbiología Clínica. Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, 2002. Consultado: 10.06.2020. Disponible en: https://seimc.org/contenidos/documentoscientificos/procedimientosmicrobiologia/seimc-procedimientomicrobiologia14.pdf
34. Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gilligan PH, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis . 2018;67(6):e1-e94.
35. Comité de l’Antibiogramme de la Société Franc¸ aise de Microbiologie. Recommandations 2019: Disponible en: http://www.sfm-microbiologie.org/UserFiles/file/casfm 2019.pdf. (Ultima visita: 18.06.2020)
36. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Twentieth Informational Supplement. CLSI document. M100-S20-U (June 2010 Update). Wayne, PA 2010.
37. García-Tello A, Gimbernat H, Redondo C, Arana DM, Cacho J, Angulo JC. Betalactamasas de espectro extendido en las infecciones del tracto urinario causadas por enterobacterias: aproximación a su conocimiento y pautas de actuación. Actas Urol Esp. 2014;38(10): 678-684.
38. Guillén R, Velázquez G, Lird G, Espínola C, Laconich M, Carpinelli L, et al. Detección molecular de belactamasas de espectro (BLEE) en enterobacterias aisladas en Asunción. Mem. Inst. Investig. Cienc. Salud . 2015;13(2):8-16.
39. Cavagnaro-SantaMaría F. Resistencia antibiótica en la infección urinaria: la historia sin fin. Bol Med Hosp Infant Mex.2014; 71(6):329-331.
40. Woodford N, Kaufmann ME, Karisik E, Hartley JW. Molecular epidemiology of multiresistant Escherichia coli isolates from community-onset urinary tract infections in Cornwall, England. J Antimicrob Chemother. 2007;59(1):106‐109.
41. Leguizamó n M, Samudio M, Aguilar G. Sensibilidad antimicrobiana de enterobacterias aisladas en infecciones urinarias de pacientes ambulatorios y hospitalizados del Hospital Central del IPS. Mem. Inst. Investig. Cienc. Salud . 2017; 15(3): 41-49
42. Villegas MV, Kattan JN, Quinteros MG, Casellas JM. Prevalence of extended-spectrum beta-lactamases in South America. Clin Microbiol Infect. 2008;14 Suppl 1:154-158.
43. Guzmán-Blanco M, Labarca JA, Villegas MV, Gotuzzo E. Extended spectrum β-lactamase producers among nosocomial Enterobacteriaceae in Latin America. Braz J Infect Dis. 2014;18:421-33.
44. Bartoloni A, Sennati S, Di Maggio T, Mantella A, Riccobono E, Strohmeyer M, et al. Antimicrobial susceptibility and emerging resistance determinants (blaCTX-M, rmtB, fosA3) in clinical isolates from urinary tract infections in the Bolivian Chaco. Int J Infect Dis. 2016;43:1-6
45. Eshetie S, Unakal C, Gelaw A, Ayelign B, Endris M, Moges F. Multidrug resistant and carbapenemase producing Enterobacteriaceae among patients with urinary tract infection at referral Hospital, Northwest Ethiopia. Antimicrob Resist Infect Control. 2015 Apr 17;4:12.
46. Melgarejo N, Martinez M, Franco R, Falcón M. Enterobacterias resistentes a Carbapenemes por producción de KPC, aisladas en hospitales de Asunción y Departamento Central. Revista de Salud Pública del Paraguay. 2013;3(1):30-5.
47. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev . 2018;31(2):e00079-17.
48. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159‐166.
49. Rivas Kiese M, Ortiz H, Almada P, Arguello R, Melgarejo N, Martínez C, Garay Z. Escherichia coli metalobetalactamasa en un hospital de alta complejidad en Paraguay. Rev. Virtual Soc. Parag. Med. Int .setiembre 2016; 3 (2): 120-123.
50. Durán L. Resistencia antimicrobiana e implicancias para el manejo de infecciones del tracto urinario Antimicrobial resistance and implications for urinary tract infection treatment. Rev Méd Clín Condes. 2018;29(2):213-221
51. Labarca J, Araos R. Resistencia antimicrobiana: Problema en aumento y soluciones escasas. Rev Chil Infect. 2009;26(Suppl1):8-9.
